Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 28.10
+0.05 (0.18%)
Nov 13, 2026, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 7.45 billion as of November 13, 2026. It is the 19,745th most valuable company in the world and the 826th biggest in Taiwan. Its market cap has decreased by 43.58% in one year.
Market Cap
7.45B
Enterprise Value
9.17B
Revenue
691.06M
Global Rank
Country Rank
#826 Taiwan
PE Ratio
n/a
ChartMarket Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 7.45B, a decrease of -55.60%. That is a compound annual growth rate of -6.96%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 13, 2026 | 7.45B | -48.87% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| OBI Pharma | 8.54B |
| TCM Biotech International | 8.07B |
| PharmaEngine | 7.83B |
| Locus Cell | 7.35B |
| Adimmune | 7.08B |
| Acepodia | 6.97B |
| AnnJi Pharmaceutical | 6.56B |
| Polaris Group | 6.39B |